<SUBMISSION>
<ACCESSION-NUMBER>0001047469-05-027291
<TYPE>SC 14D9/A
<PUBLIC-DOCUMENT-COUNT>2
<FILING-DATE>20051121
<DATE-OF-FILING-DATE-CHANGE>20051121
<SUBJECT-COMPANY>
<COMPANY-DATA>
<CONFORMED-NAME>ADVANCED NEUROMODULATION SYSTEMS INC
<CIK>0000351721
<ASSIGNED-SIC>3841
<IRS-NUMBER>751646002
<STATE-OF-INCORPORATION>TX
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>SC 14D9/A
<ACT>34
<FILE-NUMBER>005-33902
<FILM-NUMBER>051218988
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>6901 PRESTON RD.
<CITY>PLANO
<STATE>TX
<ZIP>75024
<PHONE>9723098000
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>6901 PRESTON RD.
<CITY>PLANO
<STATE>TX
<ZIP>75024
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>QUEST MEDICAL INC
<DATE-CHANGED>19920703
</FORMER-COMPANY>
</SUBJECT-COMPANY>
<FILED-BY>
<COMPANY-DATA>
<CONFORMED-NAME>ADVANCED NEUROMODULATION SYSTEMS INC
<CIK>0000351721
<ASSIGNED-SIC>3841
<IRS-NUMBER>751646002
<STATE-OF-INCORPORATION>TX
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>SC 14D9/A
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>6901 PRESTON RD.
<CITY>PLANO
<STATE>TX
<ZIP>75024
<PHONE>9723098000
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>6901 PRESTON RD.
<CITY>PLANO
<STATE>TX
<ZIP>75024
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>QUEST MEDICAL INC
<DATE-CHANGED>19920703
</FORMER-COMPANY>
</FILED-BY>
<DOCUMENT>
<TYPE>SC 14D9/A
<SEQUENCE>1
<FILENAME>a2164785zsc14d9a.htm
<DESCRIPTION>SC 14D9/A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>

<P><FONT SIZE=2>
<hr noshade width=100% align=left size=4>
<hr noshade width=100% align=left size=1> </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=5><B>SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT SIZE=2><B>WASHINGTON, D.C. 20549  </B></FONT></P>

<HR NOSHADE ALIGN="CENTER" WIDTH="120">
<P ALIGN="CENTER">


<FONT SIZE=5><B>SCHEDULE 14D-9<BR>
(RULE 14d-101)<BR>  </B></FONT><FONT SIZE=4><B>SOLICITATION/RECOMMENDATION STATEMENT<BR>
UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934<BR>
(Amendment No. 6)

  </B></FONT>

</P>

<HR NOSHADE ALIGN="CENTER" WIDTH="120">
<P ALIGN="CENTER"><FONT SIZE=4><B> Advanced Neuromodulation Systems,&nbsp;Inc.<BR>  </B></FONT><FONT SIZE=2>(Name of Subject Company) </FONT></P>

<HR NOSHADE ALIGN="CENTER" WIDTH="120">
<P ALIGN="CENTER"><FONT SIZE=4><B>Advanced Neuromodulation Systems,&nbsp;Inc.<BR>  </B></FONT><FONT SIZE=2>(Name of Person Filing Statement) </FONT></P>

<HR NOSHADE ALIGN="CENTER" WIDTH="120">
<P ALIGN="CENTER"><FONT SIZE=2><B>COMMON STOCK, PAR VALUE $.05 PER SHARE<BR>
(INCLUDING THE ASSOCIATED COMMON STOCK PURCHASE RIGHTS)<BR>  </B></FONT><FONT SIZE=2>(Title of Class of Securities) </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>00757T101<BR>  </B></FONT><FONT SIZE=2>(CUSIP Number of Class of Securities) </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>Christopher G. Chavez<BR>
President and Chief Executive Officer<BR>
Advanced Neuromodulation Systems,&nbsp;Inc.<BR>
6901 Preston Road<BR>
Plano, Texas 75024<BR>
(972)&nbsp;309-8000<BR>  </B></FONT><FONT SIZE=2>(Name, Address and Telephone Number of Person Authorized to<BR>
Receive Notice and Communications on Behalf of the Person(s) Filing Statement) </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>With
copies to each of: </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2><B>Kenneth G. Hawari<BR>
General Counsel and Executive Vice President<BR>
Advanced Neuromodulation Systems, Inc.<BR>
6901 Preston Road<BR>
Plano, Texas 75024-2508<BR>
(972) 309-8000</B></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2><B>Joseph Cialone, II<BR>
Baker Botts L.L.P.<BR>
One Shell Plaza<BR>
910 Louisiana<BR>
Houston, TX 77002-4995<BR>
(713) 229-1234</B></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2><FONT FACE="WINGDINGS">&#111;</FONT></FONT></DT><DD><FONT SIZE=2>Check
the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. </FONT></DD></DL>
<BR>

<P><FONT SIZE=2><hr
noshade width=100% align=left size=1>
<hr noshade width=100% align=left size=4> </FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2165405",CP="ADVANCED NEUROMODULATION SYSTEM",DN="1",CHK=1041727,FOLIO='blank',FILE='DISK123:[05DFW1.05DFW1391]BA1391A.;7',USER='DSCHWAR',CD='21-NOV-2005;15:56' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P><FONT SIZE=2><A
NAME="page_ja1391_1_1"> </A> </FONT> <FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Amendment No.&nbsp;6 (this "Amendment") further amends and supplements the Solicitation/Recommendation Statement on Schedule&nbsp;14D-9, as amended through the date hereof (the
"Statement"), originally filed with the Securities and Exchange Commission on October&nbsp;19, 2005, by Advanced Neuromodulation Systems, Inc., a Texas corporation (the "Company"), relating to the
third-party tender offer by Apollo Merger Corp., a Texas corporation ("Purchaser" or "Apollo") and a wholly-owned subsidiary of St. Jude Medical, Inc., a Minnesota corporation ("Parent" or
"St.&nbsp;Jude Medical"), to purchase all of the issued and outstanding shares of common stock of the Company, par value $.05 per share (together with the associated rights issued pursuant to the
Rights Agreement dated August&nbsp;30, 1996 between Quest Medical, Inc. and KeyCorp Shareholder Services, Inc., as rights agent, as amended by the Amendment to Rights Agreement dated
January&nbsp;25, 2002 between the Company and Computershare Investor Services LLC and the Second Amendment to Rights Agreement dated October&nbsp;14, 2005 between the Company and Computershare
Investor Services LLC (as so amended, the "Rights Plan")) (the "Shares"), at a purchase price of $61.25 per share, net to the seller in cash, without interest thereon, upon the terms and subject to
the conditions set forth in the Offer to Purchase, dated October&nbsp;18, 2005 (the "Offer to Purchase") and in the related Letter of Transmittal (the "Letter of Transmittal") (which, together with
the Offer to Purchase and any amendments or supplements thereto, are referred to herein collectively as the "Offer"). The Offer to Purchase and the Letter of Transmittal are filed as
Exhibits&nbsp;(a)(2) and (a)(3) this Statement, respectively. Capitalized terms used and not otherwise defined in this Amendment shall have the meanings assigned to such terms in the Statement. The
purpose of this Amendment is to attach a press release filed by St.&nbsp;Jude Medical on November&nbsp;21, 2005.

 </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2165405",CP="ADVANCED NEUROMODULATION SYSTEM",DN="1",CHK=456909,FOLIO='1',FILE='DISK123:[05DFW1.05DFW1391]JA1391A.;20',USER='DSCHWAR',CD='21-NOV-2005;15:56' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P><FONT SIZE=2><B>Item 9.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits.  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following Exhibits are attached hereto: </FONT></P>




<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="78%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="12%" ALIGN="CENTER"><FONT SIZE=1><B>Exhibit Number</B></FONT><HR NOSHADE></TH>
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="86%" ALIGN="CENTER"><FONT SIZE=1><B>Description</B></FONT><HR NOSHADE></TH>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2>(a)(1)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2>Letter to the shareholders of the Company, dated October&nbsp;18, 2005.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(2)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Offer to Purchase, dated October&nbsp;18, 2005.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(3)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Form of Letter of Transmittal.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(4)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Opinion of Piper Jaffray &amp; Co., dated as of October&nbsp;14, 2005 (included as Annex A to this Statement).*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(i)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Joint Press Release issued by the Company and St. Jude Medical on October&nbsp;16, 2005 (incorporated by reference to Exhibit&nbsp;99.1 of the Current Report on Form 8-K filed by the Company on October&nbsp;17, 2005).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(ii)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Letter to employees of the subject company dated October&nbsp;17, 2005 with attached fact sheet (incorporated by reference to Exhibit&nbsp;99.1 of the pre-commencement Solicitation/Recommendation Statement on Form 14D-9 filed by the Company on
October&nbsp;17, 2005).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(iii)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Employee Questions and Annswers, dated October&nbsp;17, 2005 (incorporated by reference to Exhibit&nbsp;99.2 of the pre-commencement Solicitation/Recommendation Statement on Form 14D-9 filed by the Company on October&nbsp;17, 2005).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(iv)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Subject company fact sheet (incorporated by reference to Exhibit&nbsp;99.3 of the pre-commencement Solicitation/Recommendation Statement on Form 14D-9 filed by the Company on October&nbsp;17, 2005).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(v)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Customer Letter, dated October&nbsp;17, 2005 (incorporated by reference to Exhibit&nbsp;99.4 of the pre-commencement Solicitation/Recommendation Statement on Form 14D-9 filed by the Company on October&nbsp;17, 2005).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(vi)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Form of Clinical Studies Letter, dated October&nbsp;17, 2005 (incorporated by reference to Exhibit&nbsp;99.5 of the pre-commencement Solicitation/Recommendation Statement on Form 14D-9 filed by the Company on October&nbsp;17, 2005).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(vii)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Form of Supplier Letter, dated October&nbsp;17, 2005 (incorporated by reference to Exhibit&nbsp;99.6 of the pre-commencement Solicitation/Recommendation Statement on Form 14D-9 filed by the Company on October&nbsp;17, 2005).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(viii)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Form of letter to employees of the Company dated October&nbsp;19, 2005.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(ix)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
International Customer Letter dated October&nbsp;27, 2005.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(x)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Press Release issued by the Company on October&nbsp;27, 2005 (incorporated by reference to Exhibit&nbsp;99.1 of the Current Report on Form&nbsp;8-K filed by the Company on October&nbsp;27, 2005).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(xi)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Employee Questions and Answers, Part II, dated October 27, 2005.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(xii)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Press Release issued by St.&nbsp;Jude Medical on November&nbsp;4, 2005.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(xiii)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Press Release issued by St.&nbsp;Jude Medical on November&nbsp;11, 2005.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(xiv)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Press Release issued by St.&nbsp;Jude Medical on November&nbsp;16, 2005.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(xv)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Press Release issued by St. Jude Medical on November&nbsp;21, 2005.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(6)(i)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Part 13 of the Texas Business Corporation Act.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(6)(ii)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Articles 5.11, 5.12, 5.13 and 5.16(E) of the Texas Business Corporation Act.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>

<!-- insert table folio -->
<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2165405",CP="ADVANCED NEUROMODULATION SYSTEM",DN="1",CHK=404318,FOLIO='blank',FILE='DISK123:[05DFW1.05DFW1391]JE1391A.;12',USER='DSCHWAR',CD='21-NOV-2005;15:56' -->
<!-- end of table folio -->


<TABLE WIDTH="78%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(e)(1)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Agreement and Plan of Merger, dated as of October&nbsp;15, 2005, among St. Jude Medical, the Purchaser and the Company (incorporated by reference to Exhibit&nbsp;2.1 to the Form 8-K filed by the Company on October&nbsp;17, 2005).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(e)(2)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Information Statement of the Company, dated October&nbsp;18, 2005 (included as Annex B hereto).*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(e)(3)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Confidentiality Agreement dated July 28, 2005 between the Company and St. Jude Medical.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(e)(4)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Special Termination Agreement between the Company and Christopher G. Chavez, President and Chief Executive Officer, dated as of April&nbsp;1, 2002.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(e)(5)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Special Termination Agreement between the Company and Mr.&nbsp;Kenneth G. Hawari, General Counsel, Executive Vice President&#151;Corporate Development and Secretary, dated as of April 1, 2002.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(e)(6)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Special Termination Agreement between the Company and Mr.&nbsp;Scott F. Drees, Executive Vice President&#151;Operations, dated as of May 25, 2001.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(e)(7)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Special Termination Agreement between the Company and Mr.&nbsp;F. Robert Merrill, III, Chief Financial Officer, dated as of May&nbsp;25, 2001.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(e)(8)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Special Termination Agreement between the Company and Mr.&nbsp;James P. Calhoun, Vice President&#151;Human Resources, dated as of May&nbsp;25, 2001.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(e)(9)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Special Termination Agreement between the Company and Mr.&nbsp;John H. Erickson, Vice President&#151;Research &amp; Development, dated as of May&nbsp;25, 2001.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(e)(10)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Special Termination Agreement between the Company and Mr.&nbsp;Stuart B. Johnson, Vice President&#151;Manufacturing, dated as of May 25, 2001.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(e)(11)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Second Amendment to Rights Agreement, dated as of October&nbsp;14, 2005.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(g)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Not applicable.</FONT></TD>
</TR>
</TABLE>


<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE ALIGN="LEFT" WIDTH="120">
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD><FONT SIZE=2>Previously
filed. </FONT></DD></DL>
<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=4,EFW="2165405",CP="ADVANCED NEUROMODULATION SYSTEM",DN="1",CHK=398697,FOLIO='blank',FILE='DISK123:[05DFW1.05DFW1391]JE1391A.;12',USER='DSCHWAR',CD='21-NOV-2005;15:56' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- SEQ=,FILE='QUICKLINK',USER=JBAKER,SEQ=,EFW="2165405",CP="ADVANCED NEUROMODULATION SYSTEM",DN="1" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(A)(5)(XV)
<SEQUENCE>2
<FILENAME>a2165405zex-99_a5xv.htm
<DESCRIPTION>EXHIBIT 99.(A)(5)(XV)
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_ns1391_1_1"> </A> </FONT> <FONT SIZE=2><B>Exhibit (a)(5)(xv)  </B></FONT></P>

<P><FONT SIZE=4>ST. JUDE MEDICAL<BR></FONT> <FONT SIZE=6>News Release... </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="10%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="28%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="28%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="28%"><FONT SIZE=1>St. Jude Medical<BR>
One Lillehei Plaza<BR>
St. Paul, Minnesota 55117<BR>
(651) 483.2000<BR>
www.sjm.com</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="10%"><FONT SIZE=2><B>Contacts</B></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="28%"><FONT SIZE=2>Laura Merriam<BR>
Investor Relations<BR>
(651) 766-3029</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="28%"><FONT SIZE=2>Angela Craig<BR>
Media Relations<BR>
(651) 481-7789</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="28%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2><B>St. Jude Medical Extends Subsequent Offering Period By Five Business Days  </B></FONT></P>

<P><FONT SIZE=2>ST. PAUL, MN, November&nbsp;21, 2005&#151;St.&nbsp;Jude Medical,&nbsp;Inc. (NYSE:STJ) announced today that the previously announced subsequent offering period of
its tender offer for all outstanding shares of common stock of Advanced Neuromodulation Systems,&nbsp;Inc. (NASDAQ:ANSI) has been extended and will now expire at 5:00&nbsp;p.m. Eastern Time on
Monday, November&nbsp;28, 2005. The subsequent offering period was previously scheduled to expire at 12:00 midnight, Eastern Time, on Friday, November&nbsp;18, 2005. </FONT></P>


<P><FONT SIZE=2>Including
those ANS shares tendered in the initial offering period, ANS shareholders have now tendered approximately 17,977,527 shares (up from 15,769,679 shares at the end of the initial offering
period that expired on November&nbsp;15, 2005), or approximately 89&nbsp;percent of the outstanding shares of ANS. St.&nbsp;Jude Medical has accepted for payment all of the ANS shares that were
validly tendered and not properly withdrawn in the offer. </FONT></P>

<P><FONT SIZE=2>St.
Jude Medical has also received notices of guaranteed delivery for 534,142 shares, representing approximately 2.6&nbsp;percent of ANS's outstanding shares. The extension of the subsequent
offering period will permit all shareholders who have not yet tendered their shares, including those shareholders who have delivered notices of guaranteed delivery but not tendered the shares
underlying those notices, to obtain the $61.25 per share offer price for their ANS shares prior to consummation of a merger. </FONT></P>

<P><FONT SIZE=2>If
at least 90&nbsp;percent of the outstanding shares of ANS common stock have been tendered by the expiration of the subsequent offering period, St.&nbsp;Jude Medical will carry out a
"short-form" merger, as permitted by Texas law. </FONT></P>

<P><FONT SIZE=2>During
the subsequent offering period, ANS shares validly tendered will be accepted and promptly paid for as they are tendered. Shareholders who tender ANS shares during such period will be paid the
same $61.25 net per share in cash consideration paid during the initial offering period. ANS shares tendered during the subsequent offering period may not be withdrawn. If the subsequent offering
period is extended, St.&nbsp;Jude Medical will issue a press release prior to 9:00&nbsp;a.m. Eastern Time on the first business day following the date the subsequent offering period was scheduled
to expire. </FONT></P>

<P><FONT SIZE=2>MacKenzie
Partners,&nbsp;Inc. is acting as information agent in connection with the tender offer and can be contacted at (800)&nbsp;322-2885 (toll free) or
(212)&nbsp;929-5500 (collect). The Dealer Manager for the tender offer is Banc of America Securities LLC. </FONT></P>

<P><FONT SIZE=2><B>About St. Jude Medical</B></FONT><FONT SIZE=2><BR>
St. Jude Medical,&nbsp;Inc. (<U>www.sjm.com</U>) is dedicated to the design, manufacture and distribution of innovative medical devices of the highest quality, offering
physicians, patients and payers outstanding clinical performance and demonstrated economic value. </FONT></P>

<P><FONT SIZE=2><B>About ANS</B></FONT><FONT SIZE=2><BR>
ANS (<U>www.ANS-medical.com</U>) designs, develops, manufacturers and markets implantable systems used to manage chronic intractable pain and other disorders of the
central nervous system. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2165405",CP="ADVANCED NEUROMODULATION SYSTEM",DN="2",CHK=160049,FOLIO='1',FILE='DISK123:[05DFW1.05DFW1391]NS1391A.;3',USER='DSCHWAR',CD='21-NOV-2005;16:11' -->
<A NAME="page_ns1391_1_2"> </A>
<BR>

<P><FONT SIZE=2><B>Forward-Looking Statements</B></FONT><BR><FONT SIZE=2><I>Any statements made regarding the proposed transaction between St.&nbsp;Jude Medical,&nbsp;Inc. and Advanced Neuromodulation Systems,&nbsp;Inc., the expected timetable
for completing the transaction, successful integration of the business, benefits of the transaction, potential clinical success, regulatory approvals, anticipated future product launches, revenues,
earnings, expected repayment of debt, market shares, market growth, market segment growth, new indications, and any other statements regarding St.&nbsp;Jude Medical's or ANS's future expectations,
beliefs, goals or prospects are forward-looking statements which are subject to risks and uncertainties, such as those described under or incorporated by reference in the Cautionary Statements section
in Item&nbsp;2 of St.&nbsp;Jude Medical's Quarterly Report on Form&nbsp;10-Q filed on November&nbsp;8, 2005 (see page&nbsp;35), and in Item&nbsp;8.01 of ANS's Current Report on
Form&nbsp;8-K filed on October&nbsp;17, 2005, and in the Outlook and Uncertainties section in ANS's Quarterly Report on Form&nbsp;10-Q for the quarter ended
September&nbsp;30, 2005 (see page&nbsp;26), and ANS's Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2004 (see page&nbsp;26). Actual results may differ
materially from anticipated results.</I></FONT></P>

<P><FONT SIZE=2><B>Additional Information<BR>  </B></FONT><FONT SIZE=2><I>This announcement is neither an offer to purchase nor a solicitation of an offer to sell shares of ANS. St.&nbsp;Jude Medical has filed a tender offer statement with the
Securities and Exchange Commission (SEC) and ANS has filed a solicitation/recommendation statement with respect to the offer. ANS shareholders are advised to read the tender offer statement regarding
the acquisition of ANS referenced in this news release, and the related solicitation/recommendation statement. The tender offer statement and the solicitation/recommendation statement contain
important information that should be read carefully before any decision is made with respect the offer. These documents are available at no charge on the SEC's web site at www.sec.gov. Shareholders
may also obtain copies of these documents without charge by requesting them from MacKenzie Partners,&nbsp;Inc., (800)&nbsp;322-2885 (toll free) or (212)&nbsp;929-5500
(collect), the Information Agent for the tender offer.</I></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=2,EFW="2165405",CP="ADVANCED NEUROMODULATION SYSTEM",DN="2",CHK=1043007,FOLIO='2',FILE='DISK123:[05DFW1.05DFW1391]NS1391A.;3',USER='DSCHWAR',CD='21-NOV-2005;16:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- SEQ=,FILE='QUICKLINK',USER=JBAKER,SEQ=,EFW="2165405",CP="ADVANCED NEUROMODULATION SYSTEM",DN="2" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SUBMISSION>
